Relationship between 18F-fluorodeoxyglucose uptake in primary lesions and clinicopathological characteristics of esophageal squamous cell carcinoma patients

Sun,Mingping; Li,Baosheng; Fu,Zheng; Wei,Yumei; Zhang,Jian; Sun,Hongfu; Li,Hongsheng; Feng,Rui

doi:10.3892/etm.2012.772

Relationship between 18F-fluorodeoxyglucose uptake in primary lesions and clinicopathological characteristics of esophageal squamous cell carcinoma patients

Authors:
- Mingping Sun
- Baosheng Li
- Zheng Fu
- Yumei Wei
- Jian Zhang
- Hongfu Sun
- Hongsheng Li
- Rui Feng
View Affiliations

Affiliations: Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China, PET/CT Center, Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China, Department of Radiation Oncology (Abdomen Section), Shandong Cancer Hospital, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China
Published online on: October 26, 2012 https://doi.org/10.3892/etm.2012.772
Pages: 170-174

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study, was to investigate the relationship between 18F‑fluorodeoxyglucose (18F‑FDG) uptake in primary tumors and the clinicopathological characteristics of esophageal squamous cell carcinoma (ESCC) patients. Patients with histopathologically diagnosed ESCC who had received a pre‑therapeutic 18F‑FDG positron emission tomography‑computed tomography (PET‑CT) scan were enrolled in the study. The maximum standardized uptake value (SUVmax) and the length of the primary tumor were measured by PET‑CT. The clinical tumor‑node‑metastasis (TNM) stage was determined mainly by PET‑CT images according to the American Joint Committee on Cancer (AJCC) staging system, 2002. A significant difference was observed in SUVmax between the length and T stage of the primary tumor (P=0.000 and P=0.017, respectively), but not in the grade of tumor differentiation (P=0.383), clinical stage (P=0.583), N staging (P=0.387), M staging (P=0.886), patient age (P=0.752) or gender (P=0.233). There was a significant positive correlation between the SUVmax and the length of the tumor (r=0.456, P=0.000) and the depth of invasion of the primary tumor (r=0.257, P=0.006). After controlling for length, no statistically significant correlation was found between T stage and SUVmax (r=0.074, P=0.537). In conclusion, these findings suggest that tumor length influences FDG uptake in ESCC tumors, and that the T stage of the primary tumor is not significantly correlated with the SUVmax after controlling for length. However, we did not find a significant correlation between the SUVmax and primary tumor differentiation and clinical stage. These data provide important information for the management of ESCC.

View Figures

View References

1	Lee JL, Park SI, Kim SB, et al: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 15:947–954. 2004. View Article : Google Scholar
2	Choi JY, Jang HJ, Shim YM, et al: ¹⁸F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med. 45:1843–1850. 2004.
3	Yuequan J, Shifeng C and Bing Z: Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. Ann Thorac Surg. 90:908–913. 2010. View Article : Google Scholar : PubMed/NCBI
4	Flamen P, Lerut A, Van Cutsem E, et al: Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 18:3202–3210. 2000.PubMed/NCBI
5	Kato H, Miyazaki T, Nakajima M, et al: The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 103:148–156. 2005. View Article : Google Scholar : PubMed/NCBI
6	Thurau K, Palmes D, Franzius C, Minin E, Senninger N, Juergens KU and Bruewer M: Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer. World J Surg. 35:608–616. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhang ZJ, Chen JH, Meng L, Du JJ, Zhang L, Liu Y and Dai HH: ¹⁸F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer. Chin Med J (Engl). 120:125–131. 2007.
8	Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E and Wood DE: Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 6:3837–3844. 2000.
9	Sepesi B, Raymond DP, Polomsky M, et al: Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer. J Gastrointest Surg. 13:2121–2127. 2009. View Article : Google Scholar : PubMed/NCBI
10	Zhong X, Yu J, Zhang B, et al: Using ¹⁸F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 73:136–141. 2009.
11	Suzuki A, Xiao L, Hayashi Y, et al: Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 117:4823–4833. 2011. View Article : Google Scholar
12	Feng R, Li MH, Kong L, Shi F, Yang GR and Yu JM: Correlation between PET-CT ¹⁸FDG uptake in primary lesions and clinicopathological parameters in esophageal carcinoma patients. Zhonghua Zhong Liu Za Zhi. 31:452–454. 2009.(In Chinese).
13	Mu DB, Wang SP, Yang WF, Fu Z, Chen XX, Sun XR and Yu JM: Correlation between FDG PET/CT and the expression of glutl and ki-67 antigen in esophageal cancer. Zhonghua Zhong Liu Za Zhi. 29:30–33. 2007.(In Chinese).
14	Cerfolio RJ and Bryant AS: Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg. 82:391–394. 2006. View Article : Google Scholar
15	Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual. 6th edition. Springer; New York, NY: 2002, View Article : Google Scholar
16	Kato H, Kuwano H, Nakajima M, et al: Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 94:921–928. 2002. View Article : Google Scholar : PubMed/NCBI
17	Buchmann I, Haberkorn U, Schmidtmann I, Brochhausen C, Buchholz HG, Bartenstein P and Hansen T: Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study. Cancer Biother Radiopharm. 23:172–180. 2008. View Article : Google Scholar : PubMed/NCBI
18	Kato H, Nakajima M, Sohda M, et al: The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 15:3196–3203. 2009. View Article : Google Scholar : PubMed/NCBI
19	Li J, Pan YD, Yin JL and Li XD: Analysis of standard uptake values of ¹⁸F-FDG PET/CT in relation to pathological classification and clinical staging of nasopharyngeal carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 28:1923–1924. 2008.(In Chinese).
20	Hsu WH, Hsu PK, Wang SJ, Lin KH, Huang CS, Hsieh CC and Wu YC: Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg. 87:1564–1568. 2009. View Article : Google Scholar : PubMed/NCBI
21	Li M, Sun Y, Liu Y, et al: Relationship between primary lesion FDG uptake and clinical stage at PET-CT for non-small cell lung cancer patients: an observation. Lung Cancer. 68:394–397. 2010. View Article : Google Scholar : PubMed/NCBI
22	Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S and Rusch V: Preoperative ¹⁸[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg. 81:1076–1081. 2006.
23	van Westreenen HL, Plukker JT, Cobben DC, Verhoogt CJ, Groen H and Jager PL: Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol. 185:436–40. 2005.PubMed/NCBI
24	Liu H, Lu L, Zhu Q, et al: Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy. Radiother Oncol. 99:181–186. 2011. View Article : Google Scholar
25	Eloubeidi MA, Desmond R, Arguedas MR, Reed CE and Wilcox CM: Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 95:1434–1443. 2002. View Article : Google Scholar : PubMed/NCBI
26	Roedl JB, Sahani DV, Colen RR, Fischman AJ, Mueller PR and Blake MA: Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. Eur Radiol. 18:2833–2840. 2008. View Article : Google Scholar : PubMed/NCBI